Corvus Pharmaceuticals (CRVS) Cash & Equivalents (2015 - 2026)

Corvus Pharmaceuticals' Cash & Equivalents history runs 12 years deep, the most recent figure standing at $40.1 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 702.2% year-over-year to $40.1 million; the TTM figure through Mar 2026 stood at $40.1 million (up 702.2% YoY), while the FY2025 annual figure was $4.6 million, down 47.64% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $40.1 million, up from $4.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $40.1 million in Q1 2026, with the low at $2.9 million in Q3 2025.
• The 5-year median for Cash & Equivalents is $12.6 million (2023), against an average of $14.7 million.
• The sharpest annual moves came in 2022 and 2026: Cash & Equivalents plunged 79.26% in 2022, then soared 702.2% in 2026.
• Corvus Pharmaceuticals' Cash & Equivalents stood at $13.2 million in 2022, then retreated by 4.1% to $12.6 million in 2023, then sank by 30.74% to $8.7 million in 2024, then plunged by 47.64% to $4.6 million in 2025, then surged by 776.35% to $40.1 million in 2026.
• Business Quant data shows CRVS's Cash & Equivalents at $40.1 million in Q1 2026, $4.6 million in Q4 2025, and $2.9 million in Q3 2025.